Pancreatic Cancer Research

ResearcherSapporo Medical UniversityActive in the last 2 years

Toshihiko Torigoe

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9463-5917; OpenAlex author ID A5072637751. Sources: OpenAlex.

Their work

Papers
6 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 6

  1. CLSPN Is Expressed in Pancreatic Cancer and Can Be a Target for Immunotherapy. Co-author DOI 10.21873/anticanres.18384↗
  2. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients. Co-author DOI 10.1111/cas.14514↗
  3. Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma. Last author DOI 10.1111/cas.14106↗
  4. Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine. Co-author DOI 10.1007/s00262-018-2217-x↗
  5. Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis? First author DOI 10.1007/s00595-015-1120-8↗
  6. Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients. Co-author DOI 10.1111/cas.12046↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoshihiko Hirohashi · 5 shared papers, 2013–2026 · strength 0.44
  2. Hideharu Miura · 1 shared paper, 2026 · strength 0.24
  3. Shoichiro Tange · 1 shared paper, 2026 · strength 0.24
  4. Yasutoshi Kimura · 4 shared papers, 2013–2019 · strength 0.21
  5. Hiroaki Shima · 4 shared papers, 2013–2019 · strength 0.21
  6. Toru Mizuguchi · 3 shared papers, 2016–2019 · strength 0.18
  7. Koichi Hirata · 3 shared papers, 2013–2019 · strength 0.14
  8. Ichiro Takemasa · 2 shared papers, 2018–2019 · strength 0.13
  9. Yuji Heike · 1 shared paper, 2020 · strength 0.10
  10. Yoshinori Ino · 1 shared paper, 2020 · strength 0.10
  11. Yoji Kishi · 1 shared paper, 2020 · strength 0.10
  12. Shutaro Hori · 1 shared paper, 2020 · strength 0.10
  13. Kazuaki Shimada · 1 shared paper, 2020 · strength 0.10
  14. Satoshi Nara · 1 shared paper, 2020 · strength 0.10
  15. Naoya Nakamura · 1 shared paper, 2020 · strength 0.10
  16. Nobuyoshi Hiraoka · 1 shared paper, 2020 · strength 0.10
  17. Minoru Esaki · 1 shared paper, 2020 · strength 0.10
  18. Hidekazu Kameshima · 2 shared papers, 2013–2018 · strength 0.09
  19. Masafumi Imamura · 2 shared papers, 2013–2018 · strength 0.09
  20. Kohzoh Imai · 1 shared paper, 2019 · strength 0.07
  21. Satoshi Wada · 1 shared paper, 2019 · strength 0.07
  22. Atsushi Miyamoto · 1 shared paper, 2016 · strength 0.05
  23. Yasuaki Tamura · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.